PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 20587040-10 2010 PDE-5 inhibitors or chemicals in the nitrate/nitrate group are currently not prohibited or tested for by the doping control agencies but some are highly dangerous to health and can lead to cardiovascular collapse, coma and death. Nitrates 37-44 phosphodiesterase 5A Homo sapiens 0-5 20587040-10 2010 PDE-5 inhibitors or chemicals in the nitrate/nitrate group are currently not prohibited or tested for by the doping control agencies but some are highly dangerous to health and can lead to cardiovascular collapse, coma and death. Nitrates 45-52 phosphodiesterase 5A Homo sapiens 0-5 16422846-0 2005 Successful withdrawal of oral long-acting nitrates to facilitate phosphodiesterase type 5 inhibitor use in stable coronary disease patients with erectile dysfunction. Nitrates 42-50 phosphodiesterase 5A Homo sapiens 65-89 16387564-1 2005 Phosphodiesterase 5 (PDE5) inhibitors have modest nitrate-like hemodynamic effects, lowering wedge pressure, pulmonary artery pressure, and systolic and diastolic arterial pressure. Nitrates 50-57 phosphodiesterase 5A Homo sapiens 0-19 16387564-1 2005 Phosphodiesterase 5 (PDE5) inhibitors have modest nitrate-like hemodynamic effects, lowering wedge pressure, pulmonary artery pressure, and systolic and diastolic arterial pressure. Nitrates 50-57 phosphodiesterase 5A Homo sapiens 21-25 16387566-5 2005 The duration of interaction between a PDE5 inhibitor and nitrate administration depends on the specific drug being studied. Nitrates 57-64 phosphodiesterase 5A Homo sapiens 38-42 16387572-6 2005 The emergency physician needs to have evidence-based guidance on how best to treat patients with potential ACS who are being treated for ED, how much time must elapse between the last dose of phosphodiesterase 5 (PDE5) inhibitor and treatment with nitrates, and how to modify treatment of patients with ACS when patients have recently used a PDE5 inhibitor. Nitrates 248-256 phosphodiesterase 5A Homo sapiens 342-346 16387572-7 2005 Additionally, patients who have been prescribed a PDE5 inhibitor should be educated on the use of nitrates and the need to inform physicians about the use of PDE5 inhibitors during all encounters so that risk can be minimized. Nitrates 98-106 phosphodiesterase 5A Homo sapiens 50-54 20394470-0 2010 Co-possession of phosphodiesterase type-5 inhibitors (PDE5-I) with nitrates. Nitrates 67-75 phosphodiesterase 5A Homo sapiens 54-58 20394470-1 2010 OBJECTIVE: Estimate the proportion of phosphodiesterase type-5 inhibitor (PDE5-I) patients who co-possess nitrates and compare the proportion of tadalafil patients dispensed nitrates to a matched control group. Nitrates 106-114 phosphodiesterase 5A Homo sapiens 74-78 20394470-7 2010 When co-possessed prescriptions were defined by overlapping exposure periods, the proportion of PDE5-I patients with co-possessed nitrates ranged from 1.44% (tadalafil) to 1.72% (vardenafil) and 2.13% (sildenafil). Nitrates 130-138 phosphodiesterase 5A Homo sapiens 96-100 20394470-9 2010 The majority (54.29%) of co-possessed PDE5-I and nitrate prescriptions had the nitrate dispensed prior to the PDE5-I prescription identified in the study cohort. Nitrates 49-56 phosphodiesterase 5A Homo sapiens 110-114 20394470-9 2010 The majority (54.29%) of co-possessed PDE5-I and nitrate prescriptions had the nitrate dispensed prior to the PDE5-I prescription identified in the study cohort. Nitrates 79-86 phosphodiesterase 5A Homo sapiens 38-42 17467673-6 2007 PDE1 and/or PDE5 are also reportedly up-regulated in chronic disease conditions such as atherosclerosis or cardiac pressure-load stress and heart failure as well as in response to long-term exposure to nitrates. Nitrates 202-210 phosphodiesterase 5A Homo sapiens 12-16 17183346-3 2007 As these phosphodiesterase 5 (PDE5) inhibitors all increase the hypotensive effects of nitrates, they are not suitable for use in patients taking nitrates for the treatment of ischaemic heart disease. Nitrates 87-95 phosphodiesterase 5A Homo sapiens 9-28 17183346-3 2007 As these phosphodiesterase 5 (PDE5) inhibitors all increase the hypotensive effects of nitrates, they are not suitable for use in patients taking nitrates for the treatment of ischaemic heart disease. Nitrates 87-95 phosphodiesterase 5A Homo sapiens 30-34 16422846-2 2005 Phosphodiesterase type 5 (PDE5) inhibitors are effective in up to 80% of men but are contraindicated in the presence of oral nitrates, because of a potentially severe hypotensive interaction. Nitrates 125-133 phosphodiesterase 5A Homo sapiens 0-24 16422846-2 2005 Phosphodiesterase type 5 (PDE5) inhibitors are effective in up to 80% of men but are contraindicated in the presence of oral nitrates, because of a potentially severe hypotensive interaction. Nitrates 125-133 phosphodiesterase 5A Homo sapiens 26-30 16422846-5 2005 MAIN OUTCOME MEASURES: Discontinuation of oral nitrates to facilitate subsequent use of PDE5 therapy. Nitrates 47-55 phosphodiesterase 5A Homo sapiens 88-92 16422846-10 2005 Forty-nine of the 52 men no longer taking nitrates were treated with a PDE5 inhibitor which was effective in 22 out of 26 (85%) patients who have completed follow-up. Nitrates 42-50 phosphodiesterase 5A Homo sapiens 71-75 16422846-13 2005 CONCLUSION: Oral nitrates can be discontinued in the presence of continuing beta-blockade and/or calcium antagonist therapy in stable coronary disease patients with ED to allow for the safe use of PDE5 inhibitors. Nitrates 17-25 phosphodiesterase 5A Homo sapiens 197-201 14622500-4 2003 PDE-5 inhibitors have been shown to be safe and effective for the therapy for ED, but remain contraindicated in patients receiving organic nitrates. Nitrates 139-147 phosphodiesterase 5A Homo sapiens 0-5 15197447-8 2004 Without any exception it applies to all three PDE 5 inhibitors that they are absolutely contraindicated in patients taking nitrate- or molsidomine-containing medications and that they may interact in particular with non-uroselective alpha-adrenoceptor blockers. Nitrates 123-130 phosphodiesterase 5A Homo sapiens 46-51 15537369-22 2004 The use of PDE5 inhibitors in the presence of oral nitrates is absolutely contraindicated. Nitrates 51-59 phosphodiesterase 5A Homo sapiens 11-15 15223851-3 2004 Both of these Pde-5 inhibitors have vasodilating properties and effects on blood pressure (BP), and like nitrates, they work through the nitric oxide cyclic guanosine monophosphate pathway. Nitrates 105-113 phosphodiesterase 5A Homo sapiens 14-19 15115189-8 2004 The one major precaution for men taking PDE5 inhibitors is to avoid concomitant administration of therapeutic and recreational nitrate preparations. Nitrates 127-134 phosphodiesterase 5A Homo sapiens 40-44 11137498-7 2000 Because PDE5 is also present in small amounts in the systemic vasculature, sildenafil can cause a synergistic and major decrease in pressure when combined with organic nitrates. Nitrates 168-176 phosphodiesterase 5A Homo sapiens 8-12 14642699-1 2003 OBJECTIVES: This study was designed to determine the time course of nitrate interaction with tadalafil, a phosphodiesterase 5 (PDE5) inhibitor with a half-life (t(1/2)) of 17.5 h. BACKGROUND: The PDE5 inhibitors augment the blood pressure (BP)-lowering effects of nitrates, yet the time course of this interaction is unclear. Nitrates 68-75 phosphodiesterase 5A Homo sapiens 106-125 14642699-1 2003 OBJECTIVES: This study was designed to determine the time course of nitrate interaction with tadalafil, a phosphodiesterase 5 (PDE5) inhibitor with a half-life (t(1/2)) of 17.5 h. BACKGROUND: The PDE5 inhibitors augment the blood pressure (BP)-lowering effects of nitrates, yet the time course of this interaction is unclear. Nitrates 68-75 phosphodiesterase 5A Homo sapiens 127-131 14642699-1 2003 OBJECTIVES: This study was designed to determine the time course of nitrate interaction with tadalafil, a phosphodiesterase 5 (PDE5) inhibitor with a half-life (t(1/2)) of 17.5 h. BACKGROUND: The PDE5 inhibitors augment the blood pressure (BP)-lowering effects of nitrates, yet the time course of this interaction is unclear. Nitrates 68-75 phosphodiesterase 5A Homo sapiens 196-200 11351772-1 2001 As a potent and selective inhibitor of cyclic guanosine monophosphate-specific phosphodiesterase 5 (PDE5), sildenafil citrate (Viagra) is safe and effective in men with erectile dysfunction (ED) of diverse aetiologies, including patients with common cardiovascular diseases who are not receiving organic nitrates or nitrate donor drugs. Nitrates 304-312 phosphodiesterase 5A Homo sapiens 100-104 11351772-1 2001 As a potent and selective inhibitor of cyclic guanosine monophosphate-specific phosphodiesterase 5 (PDE5), sildenafil citrate (Viagra) is safe and effective in men with erectile dysfunction (ED) of diverse aetiologies, including patients with common cardiovascular diseases who are not receiving organic nitrates or nitrate donor drugs. Nitrates 304-311 phosphodiesterase 5A Homo sapiens 100-104 25452706-3 2014 The mechanism of action of PDE-5 inhibitors results in a potential cumulative drop in blood pressure (BP); thus, these agents are contraindicated in patients receiving nitrates. Nitrates 168-176 phosphodiesterase 5A Homo sapiens 27-32 35436155-2 2022 OBJECTIVE: To measure temporal trends in the coprescription of nitrates and PDE5 inhibitors and to measure the association between cardiovascular outcomes and the coprescription of nitrates with PDE5 inhibitors. Nitrates 181-189 phosphodiesterase 5A Homo sapiens 195-199 35436155-9 2022 During this period, the prescription rate for PDE5 inhibitors in patients with IHD who were taking nitrates increased from an average of 0.9 prescriptions (95% CI, 0.5 to 1.2 prescriptions) per 100 persons per year in 2000 to 19.5 prescriptions (CI, 18.0 to 21.1 prescriptions) in 2018. Nitrates 99-107 phosphodiesterase 5A Homo sapiens 46-50 35436155-12 2022 CONCLUSION: From 2000 to 2018, the use of PDE5 inhibitors increased 20-fold among Danish patients with IHD who were taking nitrates. Nitrates 123-131 phosphodiesterase 5A Homo sapiens 42-46 23917809-8 2013 Side effects and interactions of PDE 5 inhibitors with other drugs have been minimal, with the exception of their coadministration with nitrates, which could lead to severe vasodilation and hypotension and therefore, their coadministration is prohibited. Nitrates 136-144 phosphodiesterase 5A Homo sapiens 33-38 26328121-8 2013 The use of PDE-5 inhibitors is absolutely contraindicated in patients taking nitrate preparations. Nitrates 77-84 phosphodiesterase 5A Homo sapiens 11-16 25410225-10 2014 The use of PDE-5 inhibitors in the presence of oral nitrates is strictly contraindicated in diabetic men, as in nondiabetic subjects. Nitrates 52-60 phosphodiesterase 5A Homo sapiens 11-16